Last reviewed · How we verify

Daily oral PrEP

University of Washington · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Daily oral PrEP is a Small molecule drug developed by University of Washington. It is currently FDA-approved. Also known as: PrEP.

Daily oral PrEP is a medication used to prevent HIV infection, studied in various clinical trials for its effectiveness in reducing the risk of sexually transmitted infections. It is typically administered in the form of Truvada, a combination of antiretroviral medications that induce an immune response to prevent HIV infection.

At a glance

Generic nameDaily oral PrEP
Also known asPrEP
SponsorUniversity of Washington
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Daily oral PrEP

What is Daily oral PrEP?

Daily oral PrEP is a Small molecule drug developed by University of Washington.

Who makes Daily oral PrEP?

Daily oral PrEP is developed and marketed by University of Washington (see full University of Washington pipeline at /company/university-of-washington).

Is Daily oral PrEP also known as anything else?

Daily oral PrEP is also known as PrEP.

What development phase is Daily oral PrEP in?

Daily oral PrEP is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing